Health Blueprint

Back to Longevity News

News summary

ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics

Source: GlobeNewswire - Biotech Financing • Published: 05 Nov 2026, 08:08

Summarized by Masters of Longevity from GlobeNewswire - Biotech Financing.

ArrayPatch closed a €3.2 million seed round to push microneedle programs toward first-in-human studies.

ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics
Key Takeaways
  • ArrayPatch raised €3.2 million to advance microneedle programs.
  • DerMap is a polymer-free microneedle platform made from medicine.
  • Preclinical GLP-1 and skin cancer programs remain unproven in humans.
Read the full article at GlobeNewswire - Biotech Financing ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?